H.C. Wainwright assumed coverage of Tourmaline Bio with a Buy rating and $48 price target. The company has a fully human monoclonal antibody with a differentiated efficacy and safety profile for thyroid eye disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRML: